Apollomics (NASDAQ:APLM) COO Yi-Kuei Chen Purchases 20,000 Shares

Apollomics Inc. (NASDAQ:APLM) COO Yi-Kuei Chen acquired 20,000 shares of the company’s stock in a transaction on Friday, August 14th. The shares were purchased at an average cost of $15.00 per share, with a total value of $300,000.00. Following the completion of the purchase, the chief operating officer directly owned 121,248 shares of the company’s stock, valued at $1,818,720. This trade represents a 19.75% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Apollomics Price Performance

Shares of APLM opened at $23.36 on Tuesday. Apollomics Inc. has a twelve month low of $3.66 and a twelve month high of $42.12. The company’s fifty day simple moving average is $18.24 and its 200-day simple moving average is $17.30.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Apollomics stock. Kestra Advisory Services LLC purchased a new position in Apollomics Inc. (NASDAQ:APLM) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned 0.40% of Apollomics at the end of the most recent reporting period. 19.13% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of Apollomics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.